Results 1 to 10 of about 1,482 (70)
Sunitinib induced hepatotoxicity in L02 cells via ROS-MAPKs signaling pathway
Sunitinib is a multi-targeted tyrosine kinase inhibitor with remarkable anticancer activity, while hepatotoxicity is a potentially fatal adverse effect of its administration.
Ting-Li Tang +5 more
doaj +1 more source
Background Since renal cell carcinoma(RCC) is insensitive to conventional chemoradiotherapy, molecularly targeted drugs are commonly used treatments for unresectable advanced RCC.
Haohao Lu +4 more
doaj +1 more source
Role of Sam68 in Sunitinib induced renal cell carcinoma apoptosis
Sunitinib is one of the first‐line targeted drugs for metastatic renal cell carcinoma (RCC) with dual effects of antiangiogensis and proapoptosis. Sam68 (Src‐associated in mitosis, 68 KDa), is found being involved in cell apoptosis.
Zeshen Wu +13 more
doaj +1 more source
Background Sunitinib is known to cause cardiotoxicity in clinical settings. However, among sunitinib-treated patients experiencing adverse cardiac events, decreased cardiac function was reportedly reversible in > 50% of the patients. We previously showed
Toshikatsu Matsui, Tadahiro Shinozawa
doaj +1 more source
Antiangiogenic tyrosine kinases inhibitors induce hypertension, which may increase the incidents of cardiovascular complications and limit their use. However, the mechanisms by which usage of TKIs results in hypertension have not been fully understood ...
Yang Liu +5 more
doaj +1 more source
Background Cell autophagy has been proposed to be involved in drug resistance therapy. However, how the long non-coding RNA (lncRNA) reduces risks of drug resistance in renal cancer (RC) cells needs a thorough inquiry.
Dechao Li +8 more
doaj +1 more source
Background Sunitinib resistance can be classified into primary and secondary resistance. While accumulating research has indicated several underlying factors contributing to sunitinib resistance, the precise mechanisms in renal cell carcinoma are still ...
Yuanlei Chen +17 more
doaj +1 more source
Receptor tyrosine kinase (RTK) inhibitors, such as sunitinib and sorafenib, remain the first-line drugs for the treatment of mRCC. Acquired drug resistance and metastasis are the main causes of treatment failure.
Luchao Li +7 more
doaj +1 more source
Considerable attention has been raised on crizotinib- and sunitinib-induced hepatotoxicity, but the underlying mechanisms need further examination. In addition, limited therapeutic strategies exist to reduce the liver damage caused by crizotinib and ...
Lin Guo +5 more
doaj +1 more source
Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma. [PDF]
Vascular endothelial growth factor (VEGF) and mammalian target of rapamycin are well-known therapeutic targets for renal cell carcinoma (RCC). Sunitinib is an agent that targets VEGF receptors and is considered to be a standard treatment for metastatic ...
Noboru Shibasaki +10 more
doaj +1 more source

